Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Share-based Compensation (IS): 2017-2023

  • Autolus Therapeutics' Share-based Compensation (IS) was N/A to $7,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $95.2 million, marking a year-over-year change of. This contributed to the annual value of $10.7 million for FY2021, which is 44.77% down from last year.
  • According to the latest figures from Q2 2023, Autolus Therapeutics' Share-based Compensation (IS) is $7,000, which was down 12.50% from $8,000 recorded in Q1 2023.
  • Over the past 5 years, Autolus Therapeutics' Share-based Compensation (IS) peaked at $79.0 million during Q4 2021, and registered a low of $7,000 during Q2 2023.
  • In the last 2 years, Autolus Therapeutics' Share-based Compensation (IS) had a median value of $8,000 in 2023 and averaged $26.3 million.
  • Data for Autolus Therapeutics' Share-based Compensation (IS) shows a peak YoY spiked of 337.14% (in 2019) over the last 5 years.
  • Quarterly analysis of 3 years shows Autolus Therapeutics' Share-based Compensation (IS) stood at $16.2 million in 2019, then followed by $79.0 million in 2021, then followed by $7,000 in 2023.
  • Its Share-based Compensation (IS) stands at $7,000 for Q2 2023, versus $8,000 for Q1 2023 and $79.0 million for Q4 2021.